サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1666185

ウェアラブル持続グルコースモニターの世界市場：2025年～2033年

Global Wearable Continuous Glucose Monitors Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ウェアラブル持続グルコースモニターの世界市場：2025年～2033年
出版日: 2025年02月24日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ウェアラブル持続グルコースモニター（CGM）の世界市場は、2024年に45億7,000万米ドルに達し、2033年には166億米ドルに達すると予測され、予測期間2025-2033年のCAGRは15.5%で成長する見込みです。

糖尿病の世界的有病率の大幅な上昇が、ウェアラブル持続グルコースモニター（CGM）市場の成長を牽引しています。世界保健機関（WHO）によると、糖尿病患者数は1990年の2億人から2022年には8億3,000万人へと劇的に増加しており、最も急激な増加は低・中所得国で起きています。糖尿病の有病率が高まるにつれて、グルコースレベルの効果的なリアルタイムモニタリングの必要性がさらに重要になります。ウェアラブルCGMは、継続的なグルコースモニタリングのための効率的で非侵襲的なソリューションを提供し、患者の状態をよりよく管理し、重篤な合併症のリスクを低減するのに役立ちます。

未治療または不十分な管理による糖尿病の影響は深刻で、失明、腎不全、心臓発作、脳卒中、下肢切断などの症状を引き起こします。2021年だけでも、糖尿病と糖尿病関連腎臓病は200万人以上の死亡の原因となっており、高血糖は心臓血管死の約11％に寄与しています。このような統計を踏まえると、ヘルスケアシステムと患者が糖尿病を管理し、生命を脅かす合併症を予防するためのより積極的な方法を模索するにつれて、持続血糖モニタリング装置の需要は増加すると予想されます。

ウェアラブルCGMは、タイムリーな介入を知らせ、合併症のリスクを低減し、糖尿病患者の全体的な生活の質を向上させることができるリアルタイムデータを個人に提供する上で、ますます不可欠になってきています。このような糖尿病管理のニーズの高まりは、ウェアラブルCGM市場の拡大を促進する重要な要因となっています。

ウェアラブル持続グルコースモニタリング（CGM）デバイスのセンサー寿命の短さと交換コストは、消費者に経済的負担を与えることで市場を大幅に抑制する可能性があります。ほとんどのCGMセンサーは7～14日ごとに交換する必要があるため、継続的な出費が頻繁に発生し、それがすぐにかさむため、長期的な使用にはコストがかかります。

当レポートでは、世界のウェアラブル持続グルコースモニター市場について調査し、市場の概要とともに、タイプ別、コンポーネント別、年齢層別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
  • 影響分析

第5章 戦略的洞察と業界の展望

  • 市場のリーダーと先駆者
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第6章 タイプ別

  • 1型糖尿病
  • 2型糖尿病

第7章 コンポーネント別

  • センサー
  • 送信機と受信機
  • ディスプレイ
  • その他

第8章 年齢別

  • 小児
  • 成人
  • 高齢者

第9章 エンドユーザー別

  • 在宅ケア
  • 病院・クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第11章 競合情勢

第12章 企業プロファイル

  • Afon Technology
  • Abbott
  • Senseonics
  • Ascensia Diabetes Care Holdings AG.
  • A. Menarini Diagnostics srl
  • Murata Manufacturing Co., Ltd.
  • Dexcom, Inc.
  • Tandem Diabetes Care, Inc.
  • Medtronic
  • Byram Healthcare Centers, Inc.

第13章 付録

目次
Product Code: MD9200

The global wearable continuous glucose monitors (CGM) market reached US$ 4.57 billion in 2024 and is expected to reach US$ 16.60 billion by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Wearable Continuous Glucose Monitors (CGMs) are advanced medical devices used to monitor glucose levels in real time. They provide continuous, real-time data on glucose fluctuations throughout the day, offering a more detailed and consistent picture of glucose levels compared to traditional blood glucose meters that provide single-point readings.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The significant rise in the global prevalence of diabetes is driving the growth of the wearable continuous glucose monitoring (CGM) devices market. The number of people living with diabetes has increased dramatically, from 200 million in 1990 to 830 million in 2022, with the most rapid rise occurring in low- and middle-income countries according to the World Health Organization. As the prevalence of diabetes grows, the need for effective, real-time monitoring of glucose levels becomes even more critical. Wearable CGMs offer an efficient, non-invasive solution for continuous glucose monitoring, helping patients better manage their condition and reduce the risk of severe complications.

The impact of untreated or poorly managed diabetes is severe, leading to conditions such as blindness, kidney failure, heart attacks, strokes, and lower limb amputations. In 2021 alone, diabetes and diabetes-related kidney disease were responsible for over 2 million deaths, with high blood glucose contributing to around 11% of cardiovascular deaths. Given these statistics, the demand for continuous glucose monitoring devices is expected to increase as healthcare systems and patients seek more proactive ways to manage diabetes and prevent life-threatening complications.

Wearable CGMs are becoming increasingly vital in providing individuals with real-time data that can inform timely interventions, reduce the risk of complications, and improve the overall quality of life for people with diabetes. This growing need for diabetes management is a key factor driving the expansion of the wearable CGM market.

High Sensor Replacement Costs

The short sensor lifespan and replacement costs of wearable continuous glucose monitoring (CGM) devices can significantly restrain the market by creating a financial burden for consumers. Most CGM sensors need to be replaced every 7 to 14 days, resulting in frequent ongoing expenses that can quickly add up, making long-term use costly.

Segment Analysis

The global wearable continuous glucose monitors (CGM) market is segmented based on type, components, age group, end-user, and region.

Product Type:

Sensors segment is expected to dominate the global wearable continuous glucose monitors (cgm) market share

The sensors component segment is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to their essential role in providing real-time, accurate glucose measurements. Sensors are the core technology behind CGMs, as they continuously monitor blood glucose levels through interstitial fluid, offering users detailed and up-to-date information. With the increasing demand for more precise, real-time monitoring, advancements in sensor technology have enabled the development of more accurate, smaller, and longer-lasting devices.

Moreover, innovations in sensor design, such as improved accuracy, reduced size, and extended wear times, are driving the segment's growth. As people with diabetes seek more efficient and convenient ways to manage their condition, the demand for CGM systems with advanced sensors is growing. This makes the sensors segment a key driver in the wearable CGM market, as it directly impacts the overall performance and reliability of these devices.

Geographical Analysis

North America is expected to hold a significant position in the global wearable continuous glucose monitors (CGM) market share

North America is expected to dominate the wearable continuous glucose monitoring (CGM) devices market due to a combination of factors. The increasing technological advancements, rising number of diabetic patients, and increasing number of product launches are expected to hold the region in the dominant position in the global market.

The region has a high prevalence of diabetes, driving the demand for advanced diabetes management solutions. The high incidence of diabetes in North America, particularly in the United States, is significantly driving the demand for wearable continuous glucose monitoring (CGM) devices. In 2021, an estimated 29.7 million people, or 8.9% of the U.S. population, were diagnosed with diabetes. This growing prevalence, including 352,000 children and adolescents under the age of 20, highlights the urgent need for effective and convenient ways to monitor glucose levels continuously. As the number of diabetes cases continues to rise, the demand for solutions like CGMs, which provide real-time, accurate glucose data and help individuals manage their condition more effectively.

Additionally, market players are increasingly innovating the advanced wearable CGMs that are gaining approvals from the Food and Drug Administration (FDA). For instance, in March and June 2024, Dexcom and Abbott received clearance from the Food and Drug Administration (FDA) for their over-the-counter (OTC) continuous glucose monitors. While these devices utilize the same hardware as previous CGMs, they are designed for a different group of users, individuals who do not require insulin. Increasing approvals for products, such as over-the-counter continuous glucose monitors from companies are expected to drive the North American market by expanding accessibility to glucose monitoring solutions. This will cater to a broader range of users, including those without insulin dependence. Thus, the above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the wearable continuous glucose monitors (CGM) market include Afon Technology, Abbott, Senseonics, Ascensia Diabetes Care Holdings AG., A. Menarini Diagnostics srl, Murata Manufacturing Co., Ltd., Dexcom, Inc., Tandem Diabetes Care, Inc., Medtronic and Byram Healthcare Centers, Inc. among others.

Key Developments

  • In September 2024, Abbott launched its latest wearable, the Lingo continuous glucose monitor, now available for over-the-counter purchase. Unlike traditional devices designed for diabetics, Lingo is tailored for health-conscious individuals who want to track their glucose levels without requiring prior medical approval.
  • In February 2024, Know Labs, Inc. unveiled the KnowU, its wearable non-invasive continuous glucose monitor (CGM). The company first introduced the prototype in June 2023, with the KnowU being the outcome of an accelerated eight-month development process.
  • In January 2025, Samsung announced that it is developing a highly anticipated feature for wearable technology: a non-invasive continuous glucose monitor.
  • In April 2024, Senseonics Holdings, Inc. announced that their Eversense device has received the integrated CGM (iCGM) designation from the U.S. Food and Drug Administration (FDA).

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Wearable Continuous Glucose Monitors (CGM) Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Component
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Diabetes
    • 4.1.2. Restraints
      • 4.1.2.1. High Sensor Replacement Costs
    • 4.1.3. Opportunity
  • 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Type 1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type 2 Diabetes

7. By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 7.1.2. Market Attractiveness Index, By Component
  • 7.2. Sensors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Transmitters and Receivers
  • 7.4. Displays
  • 7.5. Others

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Children*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adults
  • 8.4. Elders

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Homecare Settings*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospitals & Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Afon Technology*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Abbott
  • 12.3. Senseonics
  • 12.4. Ascensia Diabetes Care Holdings AG.
  • 12.5. A. Menarini Diagnostics srl
  • 12.6. Murata Manufacturing Co., Ltd.
  • 12.7. Dexcom, Inc.
  • 12.8. Tandem Diabetes Care, Inc.
  • 12.9. Medtronic
  • 12.10. Byram Healthcare Centers, Inc.
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us